

# THE EFFECT OF COLD ATMOSPHERIC PLASMA IN BLADDER CANCER CELLS




#### Tavares-Silva E (1,2), Neves AR (1), Abrantes AM (1,3,4), Silva-Teixeira R (1), Figueiredo A (2), Botelho MF (1,3,4)


1-Biophysics Institute, Faculty of Medicine, University of Coimbra, Portugal; 2-Department of Urology and Transplantation, CHUC, Coimbra, Portugal; 3-Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Portugal; 4-CNC.IBILI, University of Coimbra, Portugal;

## INTRODUCTION

Bladder cancer (BC) is a solid tumor with high recurrence rates. It is the sixth tumor with the highest incidence and the eighth one with the highest mortality in the world.





### RESULTS



#### Decrease of metabolic activity for both cell lines

#### II. Evaluation of protein content:






Decrease of protein content for both cell lines

### III. Evaluation of oxidative stress and antioxidant defense:


#### a) Intracellular production of peroxides:






#### **METHODS:**

5% FBS




Decrease of intracellular production of peroxides for both cell lines

#### b) Intracellular production of radical superoxide:



Increase of intracellular production of radical superoxide for TCCSUP cell line

#### c) GSH levels:




No significant difference in expression of GSH levels for both cell lines

FOLLOW US ON: 🔰@sutr\_nesu

f /sutr.chuc HOMEPAGES: sutr-chuc.pt nesu.pt

Cytotoxicity results show that CAP treatment was able to induce a significant reduction of total protein content and metabolic activity even after short periods of exposure. These outcomes obtained encourage further studies. CAP can potentially offer a minimally-invasive option that allows specific cell removal without interfering with the whole tissue.

## ON GOING



The authors would like to thank Foundation for Science and Technology (FCT) through PEst-UID/NEU/04539/2013 and FEDER-COMPETE (FCOMP-01-0124-CONTACT FEDER-028417 and POCI-01-0145-FEDER-007440) for financial support. We also would like to thank APU (Portuguese Association of Urology).